Eligibility for a Wegovy savings card turns on three gates in sequence. Who pays your drug benefit, whether that plan covers the drug at all, and whether the prescription matches the approved indication. Fail the first gate and nothing else matters. Pass all three and the size of the reduction still depends on the coverage sitting underneath it.
Gate one: who pays for your prescriptions
The first question a manufacturer program asks is not about weight, age, or diagnosis. It is about the payer on your pharmacy benefit. Commercial coverage from an employer or a marketplace plan is what these programs are designed around. Coverage through Medicare, Medicaid, TRICARE, the VA, or another federal or state health program takes a person out of scope entirely.
This is not a marketing choice. Federal law restricts manufacturers from giving anything of value that could induce a beneficiary to choose a particular drug paid for by a government program, so copay assistance is structured to exclude those beneficiaries. The rule applies whether or not the person is wealthy, and whether or not the plan actually covers the drug.
Medicare adds a second layer. Part D has historically been prohibited from paying for drugs prescribed only for weight loss, so a Medicare beneficiary can be shut out of both the card and the coverage at the same time.
Gate two: whether the plan covers the drug
Copay assistance reduces a copay. If there is no copay because the plan excludes anti-obesity medication as a benefit category, the largest advertised reduction is not available. Programs of this kind usually publish two eligibility tiers: one for people whose commercial plan covers the drug, and a much smaller allowance for people whose commercial plan does not.
Anyone reading a headline number should find out which tier applies to them before treating that number as their price. Employer carve-outs for weight management are common, and the exclusion applies to the whole category rather than to one brand, so switching from Wegovy to another agent in the same class usually produces the same result.
Gate three: the prescription itself
Assistance programs are tied to the approved indication on the label. Wegovy is approved for chronic weight management in adults and adolescents meeting body mass index thresholds, with an added requirement of a weight-related condition at the lower threshold, and it carries a separate cardiovascular indication in adults with established cardiovascular disease.
A prescription written outside those bounds may still be legal but usually falls outside program terms. The same applies to a prescription for a different semaglutide product. Ozempic is approved for type 2 diabetes, not weight management, and it has its own program with its own rules. The two are not interchangeable for assistance purposes even though they share an active molecule.
How the three gates screen people out
| Gate | What is checked | Who it screens out |
|---|---|---|
| Payer type | Whether a government program pays your drug benefit | Medicare, Medicaid, TRICARE, VA, state program beneficiaries |
| Plan coverage | Whether the commercial plan covers the drug | Anyone whose employer carves out weight management |
| Prescription | Indication, product, and prescriber status | Off-label use, wrong brand, expired prescription |
| Program terms | Activation, annual maximum, program year | Anyone who hits a cap or misses re-enrollment |
| Residency | Where you live and fill the prescription | Patients outside the country or in excluded states |
The terms most people never read
Even after all three gates, program terms limit what the card does. Almost all of them carry an annual maximum benefit, and once that ceiling is reached the card stops reducing anything for the rest of the program year. Most reset on a calendar cycle rather than on the anniversary of enrollment, which means a person who starts in autumn can burn through a full year of benefit in a few months.
Programs also reserve the right to change amounts, eligibility rules, and end dates at any time, and they do change. A figure quoted in a forum post from last year is not evidence of what the program pays today. The only current terms are the ones on the manufacturer’s own program page on the day you fill.
Anyone weighing the cash side against a capped card should also look at what the direct-pay market quotes, since those figures are set outside the insurance system entirely. Ro, LillyDirect, Henry Meds, and HealthRX all publish monthly pricing a shopper can read before enrolling in anything, and the HealthRX summary of Wegovy cost is one plain reference among them. Each is a separate provider, so treating every quote on its own terms rather than assuming they match is the sensible way to compare.
Where diagnosis and prior authorization overlap
Eligibility for the card and approval by the plan are separate decisions made by different parties, and they use overlapping evidence. Prior authorization commonly asks for body mass index, a documented weight-related condition, and sometimes proof of a supervised lifestyle attempt. Recent guidance on defining clinical obesity pushes toward assessment based on measured health impairment rather than body mass index alone, and plan criteria have not all caught up with that.
The practical consequence is that a patient can be eligible for the card and still unable to use it, because the underlying claim never adjudicates. The card is second in line. It cannot fix a rejected primary claim.
What eligibility does not settle
Passing every gate produces a copay, not a price guarantee. The number moves with your deductible status, your plan’s tier placement, and how much of the annual maximum you have already used. Two people with identical cards and identical prescriptions can pay very different amounts in the same month.
People who fail gate one or gate two are usually looking at cash-pay options instead, either the manufacturer’s own direct channel for the approved product or a compounded preparation through a supervised telehealth practice. Compounded versions sit outside the FDA approval system, a compounding pharmacy prepares them against a prescription, and no brand assistance program applies to them. Pricing is published openly on that route for the same reason: a provider such as formblends.com quotes a flat monthly figure rather than an insurance-dependent estimate, which is the comparison someone locked out of the card actually needs.
Frequently asked questions
Does income affect eligibility for a Wegovy savings card?
Generally not. Manufacturer copay cards screen on insurance type rather than income, so a high earner with commercial coverage qualifies while a low-income Medicaid beneficiary does not. Income-based help usually comes from separate patient assistance programs or independent charitable foundations, which apply different tests entirely.
Can a spouse’s plan be used to qualify?
Eligibility follows the plan that actually pays the pharmacy claim for the patient. If the patient is covered as a dependent on a commercial plan, that plan is the one assessed. Being married to someone with commercial coverage does not help if the patient’s own benefit runs through a government program.
Why does the advertised amount not match what the pharmacy charges?
The headline figure usually assumes commercial coverage that already pays for the drug, with the card reducing what is left. Without that coverage the allowance is much smaller, and once the annual maximum is exhausted the card contributes nothing for the remainder of the program year.
Does a diabetes diagnosis help with Wegovy eligibility?
Not directly. Wegovy is approved for chronic weight management and cardiovascular risk reduction, not for glycemic control, so a diabetes diagnosis points toward a different product with a different program. Coverage decisions for the two indications are handled separately by most plans.
Do program terms carry over if the prescription changes dose?
Usually yes within the same product, since the card is tied to the product rather than the strength. Moving to a different brand means a different manufacturer program and a fresh eligibility check, and any benefit already used under the first program does not transfer.
